Clinical trials: Stereotactic Body Radiation Therapy
Pancreatic Cancer
Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
This study is an open-label, single-arm Phase II clinical study to evaluate the efficacy and safety of ivonescimab(AK112/SMT112) in combination with stereotactic body radiation therapy and chemotherapy in patients with pancreatic…
- Trial name
- NCT06491472
- Testing
- Ivonescimab, Gemcitabine, Nab paclitaxel
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Prostate Cancer
Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)
Multicenter, open-label, parallel-group, phase II randomized study in patients with oligometastatic prostate cancer with 1-3 asymptomatic metastases of the soft tissue or bone.
- Trial name
- LUST (NCT05893381)
- Testing
- [177Lu]Lu-PSMA I&T, Stereotactic Radiotherapy
- Where
- 2 sites in Italy
- Volunteers
- 70 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Hepatocellular Carcinoma
Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01)
Although sorafenib is the standard treatment for hepatocellular carcinoma with portal vein invasion, the outcome of these patients remains very poor, with a median survival time of 5.5 to 7.2 months.
- Trial name
- ISBRT01 (NCT04167293)
- Testing
- stereotactic body radiotherapy, Sintilimab
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Mian XI
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
This phase II trial compares the effect of adding proton spatially fractionated radiotherapy (SFRT) or photon stereotactic body radiotherapy (SBRT) to standard immunotherapy pembrolizumab before surgery (neoadjuvant) in treating…
- Conditions
- Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT07783581
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Non Small Cell Lung Cancer, Lung Neoplasms
SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC
This is a prospective, single-arm phase II clinical study. It intends to evaluate the efficacy and safety of stereotactic radiation therapy (SRT) combined with envafolimab and endostar as first-line treatment in stage IV…
- Trial name
- Endouble 2 (NCT07818304)
- Testing
- Stereotactic Radiation Therapy, Envafolimab, Endostar
- Where
- China
- Volunteers
- 61 people
- Sponsor
- The First People's Hospital of Lianyungang
Prostate Cancer
Metabolomic Study for Localized Prostate Cancer
Prostate cancer is a common disease in men treated using surgery, radiation therapy and/or hormonal therapy. Clinical prognosis relates to stage and grade of disease.
- Trial name
- NCT01968538
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Georgetown University
Low or Intermediate Risk Prostate Cancer
Phase I Study MR-guided SBRT to PCa
1) investigate the feasibility, tolerance, and safety of dose escalation via MR-guided stereotactic body radiation therapy and simultaneous integrated boost to the dominant intraprostatic lesions (DILs), 2) to assess the…
- Trial name
- MRgRTPCa (NCT03935308)
- Testing
- MR guided Linear Accelerator
- Where
- United States
- Sponsor
- Henry Ford Health System
Pancreatic Cancer
Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma
This study is designed to investigate the safety of intraoperative radiation therapy (IORT) in patients with localized pancreatic cancer undergoing surgical resection after neoadjuvant chemotherapy and stereotactic body radiation…
- Trial name
- NCT05141513
- Testing
- High Dose Rate Brachytherapy (HDR) Intraoperative Radiation Therapy (IORT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Cancer
Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease
The purpose of this study is to determine whether stereotactic body radiation therapy (SBRT) combined with checkpoint blockaded immunotherapy (CBI) will improve the response to the anticancer treatment compared to CBI alone in…
- Trial name
- NCT02843165
- Testing
- Checkpoint blockade immunotherapy, Checkpoint blockade immunotherapy plus SBRT
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- University of California, San Diego
Colorectal Cancer, Liver Metastases
Synergism of Immunomodulation and Tumor Ablation
This is a single-arm, open-label, multi-center early phase II study. This proof of concept study will investigate whether the combined use of local tumor ablation/radiation plus immunomodulating drugs may induce a significant…
- Trial name
- ILOC (NCT03101475)
- Testing
- Durvalumab (MEDI4736), Tremelimumab, Sterotactic body radiation therapy (SBRT)
- Where
- 10 sites in Austria, France and 4 more
- Volunteers
- 22 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lung Cancer, Radiotherapy
Stereotactic Radiotherapy With Different Fractionation Modes for the Early Lung Cancer
The goal of this observational study is to study the efficacy and safety of stereotactic body radiotherapy (SBRT) with different fractionation modes for early lung cancer.
- Conditions
- Lung Cancer, Radiotherapy, Stereotactic Body Radiotherapy, Fractionation
- Trial name
- DSBRT-1 (NCT05802641)
- Testing
- SBRT
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Third Hospital
Breast Cancer, Brain Metastases
Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases
Brain metastases occur in 30-50% of patients with metastatic HER2-positive breast cancer. Pyrotinib is an irreversible pan-ErbB receptor tyrosine kinase inhibitor (TKI) with activity against epidermal growth factor receptor…
- Conditions
- Breast Cancer, Brain Metastases, HER2-positive Breast Cancer
- Trial name
- NCT04582968
- Testing
- Pyrotinib Plus Capecitabine combined with brain radiotherapy
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Fudan University
High Risk Prostate Cancer
PRospective Observational Study of STereotactic Body rAdiation Therapy With Androgen Deprivation Therapy for Organ-confined High-risk Prostate Cancer: the PROSTAR Trial
Prostate Cancer (PCa) is the second most common malignancy and the 5th common cause of cancer-related mortality in men worldwide.
- Trial name
- PROSTAR (NCT06949254)
- Where
- 3 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Istituto Clinico Humanitas
NSCLC Stage IV, Metastatic Disease
IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study
This will be a phase II trial testing if the combination of stereotactic ablative body radiotherapy (SABR) and L19-IL2 improve the progression-free survival in patients with limited metastatic non-small cell lung cancer (NSCLC).
- Trial name
- IMMUNOSABR2 (NCT03705403)
- Testing
- Darleukin, Radiation
- Where
- 15 sites in Belgium, France and 4 more
- Volunteers
- 88 people
- Sponsor
- Maastricht University Medical Center
Recurrent Melanoma, Stage IV Skin Melanoma
Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma
This phase II trial studies how well stereotactic body radiotherapy and ipilimumab work in treating patients with stage IV melanoma.
- Trial name
- NCT01970527
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Washington
Oligometastatic Disease, Metastases
Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease
This prospective national multicenter observational and interventional study aims to assess the longitudinal disease trajectory of patients with oligometastatic disease (OMD) who receive local metastasis-directed therapy.
- Conditions
- Oligometastatic Disease, Metastases, Ablation Techniques, Radiotherapy
- Trial name
- OLIGO-DK (NCT06356779)
- Testing
- Local ablative therapy (LAT)
- Where
- 11 sites in Denmark
- Volunteers
- 1,200 people
- Sponsor
- Gitte Fredberg Persson MD PhD
Renal Cell Carcinoma, Radiotherapy
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
The objective of this single-center clinical study was to evaluate the disease control rate(DCR) and safety of multimodal radiotherapy in the treatment of patients with renal cell carcinoma (RCC) progressed after prior…
- Conditions
- Renal Cell Carcinoma, Radiotherapy, Immune Checkpoint Inhibitor
- Trial name
- NCT06255223
- Testing
- High-dose Radiotherapy (HDRT), Low-dose Radiotherapy (LDRT), Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Jinling Hospital, China
TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
The purpose of this study is determine if receiving stereotactic body radiation(SBRT) when participants' metastatic tumors have just begun to grow increase the length of time before disease gets worse
- Conditions
- TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC, NSCLC Stage IV
- Trial name
- NCT03808662
- Testing
- Sterotactic Body Radiotherapy/SBRT, Standard of care
- Where
- 10 sites in United States, Canada
- Volunteers
- 107 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer, Stereotactic Body Radiotherapy
Stereotactic Body Radiotherapy for Lung Lesions With Markerless Tracking (MLT) on the VERO® SBRT System
Stereotactic Body Radiotherapy (SBRT) delivers an ablative dose of radiation to tumours, with high precision. This technique offers an alternative to surgery for lung lesions.
- Conditions
- Lung Cancer, Stereotactic Body Radiotherapy, Lung Diseases, Lung Cancer Metastatic
- Trial name
- SBRT_LOV (NCT06722885)
- Testing
- Standard radiotherapy treatment
- Where
- Belgium
- Sponsor
- Universitair Ziekenhuis Brussel
Bystander Effect, Abscopal Effect
SBRT-based PArtial Tumor Irradiation of HYpoxic Segment
This study uses an unconventional radiotherapy schedule developed at our institute, consisting of a short course high-dose partial irradiation targeting exclusively the hypoxic segment of a bulky tumors, which in our preliminary…
- Conditions
- Bystander Effect, Abscopal Effect, Unresectable Malignant Solid Neoplasm, Bulky Tumors
- Trial name
- SBRT-PATHY (NCT04168320)
- Testing
- SBRT-PATHY (SBRT-based PArtial Tumor irradiation targeting HYpoxic segment)
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Klinikum Klagenfurt am Wörthersee
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.